protocol
natur
protocol
past
two
decad
sever
strategi
emerg
character
nglycan
glycoprotein
identifi
glycosit
recogn
use
cellular
glycosyl
machineri
sever
method
employ
endoglycosidas
pngase
f
pngase
releas
glycan
protein
follow
analysi
glycoform
use
ms
highperform
liquid
chromatographi
hplc
without
prior
derivat
msbase
method
provid
composit
molecular
ion
annot
highmannos
complextyp
glycan
consist
biosynthet
principl
furthermor
tandem
mass
spectra
derivat
nglycan
gener
matrixassist
laser
desorptionion
nglycan
contribut
fold
stabil
function
protein
decor
produc
transfer
glycan
precursor
sequon
asnxthrser
follow
enzymat
trim
highmannosetyp
core
sequenti
addit
monosaccharid
gener
complextyp
hybrid
glycan
process
mediat
concert
action
multipl
enzym
produc
mixtur
relat
glycoform
glycosit
make
analysi
glycosyl
difficult
address
analyt
challeng
develop
robust
semiquantit
mass
spectrometri
ms
base
method
determin
degre
glycan
occup
glycosit
proport
nglycan
process
highmannos
type
complex
type
applic
virtual
glycoprotein
complet
analysi
conduct
protein
provid
detail
descript
method
includ
procedur
proteolyt
digest
glycoprotein
specif
nonspecif
proteas
ii
denatur
proteas
heat
iii
sequenti
treatment
glycopeptid
mixtur
two
endoglycosidas
endo
h
pngase
f
creat
uniqu
mass
signatur
three
glycosyl
state
iv
lcmsm
analysi
v
data
analysi
identif
quantit
peptid
three
glycosyl
state
full
coverag
sitespecif
glycosyl
glycoprotein
achiev
thousand
highconfid
spectra
hit
glycosit
protocol
perform
experienc
technician
studentpostdoc
basic
skill
proteom
experi
take
complet
protocol
natur
protocol
maldi
electrospray
ioniz
esi
ms
wide
use
character
detail
structur
inform
nglycan
express
differ
biolog
system
freeli
avail
softwar
tool
grit
toolbox
http
wwwgritstoolboxorg
abl
automat
process
annot
archiv
glycom
data
highthroughput
manner
hplc
method
reli
retent
time
nglycan
standard
identif
glycan
speci
method
support
experi
use
glycosidas
digest
andor
permethyl
analysi
provid
addit
support
structur
assign
method
find
wide
util
character
glycosyl
highli
studi
glycoprotein
immunoglobulin
eg
igg
detect
individu
differ
nglycan
serum
glycoprotein
although
method
provid
key
inform
natur
glycoform
present
glycoprotein
rel
abund
reveal
glycosit
util
extent
glycosit
occupi
number
proteomicsbas
method
focu
identif
glycosit
util
ost
degre
site
occupi
glycan
basic
strategi
immobil
glycopeptid
use
lectin
coupl
periodatetr
glycopeptid
hydrazideactiv
bead
peptid
releas
bound
glycan
endoglycosidas
eg
pngase
f
process
convert
asnxthrser
sequenc
aspxthrser
reaction
perform
h
creat
mass
differ
asn
asp
msm
analysi
elut
peptid
provid
posit
identif
site
glycosyl
method
particularli
use
survey
complex
biolog
system
whole
cell
tissu
identifi
protein
glycosyl
recent
major
advanc
glycoproteom
msm
method
analyz
intact
glycopeptid
determin
glycoform
present
glycosit
base
combin
mass
glycopeptid
nglycan
protocol
natur
protocol
figur
applic
protocol
character
sitespecif
nglycan
process
recombin
glycoprotein
therapeut
serum
glycoprotein
ad
sitespecif
nglycan
process
recombin
glycoprotein
therapeut
igg
igm
b
well
serum
glycoprotein
transferrin
c
fetuin
set
peptid
modif
display
least
one
three
peak
area
least
data
obtain
least
six
independ
experi
mean
sem
plot
adapt
ref
natur
publish
group
asparaginelinkedglycan
nglycan
among
common
import
posttransl
modif
protein
critic
role
fold
conform
stabil
protein
particip
ligand
intraand
intercellular
recognit
hostpathogen
interact
alter
biosynthesi
nglycan
associ
mani
diseas
cancer
influenza
aid
exampl
increas
level
underprocess
highmannosetyp
glycan
report
occur
breast
cancer
progress
mice
human
broadli
neutral
antibodi
bnab
highli
glycosyl
hiv
envelop
glycoprotein
includ
underprocess
highmannos
glycan
epitop
wherea
other
requir
fulli
process
complextyp
structur
contain
sialic
acid
structur
nglycan
affect
activ
pharmacodynam
glycoprotein
biotherapeut
care
choic
cell
line
use
express
protein
growth
condit
purif
method
control
consist
nglycosyl
need
given
import
nglycan
structur
function
glycoprotein
increas
need
robust
method
analysi
nlink
glycosyl
integr
state
art
proteom
complic
analysi
inher
divers
nglycan
structur
present
glycoprotein
consequ
nontemplatedriven
biosynthesi
begin
en
bloc
transfer
glc
man
glcnac
lipidlink
glycosyl
donor
nascent
polypeptid
oligosaccharyltransferas
ost
sequencedefin
glycosit
asnxthrser
x
amino
acid
residu
except
prolin
although
none
protein
analyz
present
studi
contain
atyp
glycosyl
site
nxcysval
site
verifi
previou
studi
presenc
glycan
intact
glycopeptid
illustr
figur
glycan
subject
trim
remov
glucos
residu
highmannosetyp
glycan
trim
conserv
man
glcnac
core
follow
addit
sugar
sequenti
action
glycosyltransferas
produc
highli
relat
set
complextyp
structur
fig
moreov
glycoprotein
one
glycosit
process
site
may
differ
base
access
glycan
process
enzym
inde
well
document
exampl
protein
contain
highmannosetyp
glycan
one
glycosit
highli
process
complextyp
glycan
site
igm
influenza
hemagglutinin
hiv
envelop
glycoprotein
major
limit
approach
rel
low
abund
glycopeptid
protein
digest
mixtur
well
inher
low
ioniz
effici
glycopeptid
ms
analysi
reason
glycopeptid
typic
enrich
peptid
digest
prior
ms
analysi
differ
purif
method
hydrophil
interact
chromatographi
hilic
hydrazid
chemistri
despit
use
differ
fragment
method
includ
collisioninduc
dissoci
cid
highenergi
collis
dissoci
hcd
electrontransf
dissoci
etd
inher
heterogen
glycoform
glycosyl
site
well
difficulti
obtain
good
peptid
backbon
fragment
peptid
larg
glycan
imped
comprehens
identif
intact
glycopeptid
annot
lcmsm
data
experi
possibl
use
commerci
algorithm
byonic
http
wwwproteinmetricscomproductsbyon
howev
quantit
assess
rel
abund
glycan
structur
detect
glycosit
still
substanti
challeng
due
unknown
ioniz
effici
peptid
glycoform
especi
sialic
acidcontain
structur
moreov
glycopeptid
enrich
prior
analysi
peptid
glycan
lost
degre
glycosit
occup
assess
protocol
describ
aros
need
hiv
vaccin
effort
robust
semiquantit
glycoproteom
method
would
establish
occup
nglycan
glycosit
ii
assess
degre
glycan
process
highmannos
type
complex
type
need
stem
fact
primari
candid
vaccin
hiv
envelop
glycoprotein
trimer
env
contain
nglycan
creat
glycan
shield
protect
attack
immun
system
despit
dens
cover
nglycan
bnab
bind
hiv
env
occur
patient
importantli
bnab
show
interact
highmannos
glycan
wherea
other
show
depend
complextyp
glycan
thu
support
ration
design
hiv
env
vaccin
develop
method
could
assess
proport
highmannosetyp
complextyp
nglycan
glycosit
hiv
env
howev
demonstr
method
broadli
applic
glycoprotein
one
key
aspect
method
sequenti
use
two
endoglycosidas
treatment
introduc
uniqu
mass
signatur
glycosit
carri
glycan
highmannosehybridtyp
glycan
complextyp
glycan
illustr
figur
proteas
digest
endoglycosidas
h
endo
h
use
remov
highmannoseand
hybridtyp
nglycan
least
mannos
residu
fig
enzym
leav
glcnacasn
residu
add
peptid
mass
subsequ
remain
complex
nglycan
remov
pngase
f
presenc
h
remov
glycan
convert
asn
asp
addit
peptid
mass
peptid
carri
glycosit
asnxthrser
asn
unoccupi
glcnacasn
endo
htreat
asp
pngase
ftreat
display
similar
ioniz
effici
ms
analysi
allow
us
use
ion
intens
peak
area
quantifi
rel
distribut
three
glycosyl
state
glycosit
detect
anoth
distinguish
featur
method
use
multipl
proteas
gener
thousand
spectra
hit
glycosit
result
sequenc
coverag
simpl
strategi
effect
convert
glycoproteom
analysi
proteom
analysi
allow
use
robust
proteom
softwar
analyz
data
highthroughput
manner
major
advantag
method
provid
glimps
site
occup
process
nglycan
glycosyl
site
provid
semiquantit
analysi
three
glycosyl
state
complet
analysi
conduct
protein
even
complex
glycoprotein
hiv
env
compris
glycosit
per
monom
note
hybrid
structur
potenti
contain
sialic
acid
see
fig
includ
highmannosetyp
categori
cleav
endo
h
howev
hybrid
structur
typic
low
abund
one
major
limit
method
glycan
structur
remov
lcmsm
class
glycan
infer
specif
endoglycosidas
msm
method
base
analysi
intact
glycopeptid
provid
inform
spectra
glycan
individu
glycosit
complementari
protocol
provid
semiquantit
inform
site
occup
glycan
process
howev
neither
method
provid
precis
structur
complet
glycosid
linkag
monosaccharid
although
protocol
design
sitespecif
glycosyl
analysi
purifi
glycoprotein
principl
applic
morecomplex
protein
sampl
membraneenvelop
virus
eg
hiv
influenza
viru
coronaviru
compris
protein
howev
describ
experiment
design
section
modif
protocol
would
need
survey
glycosit
complex
sampl
cell
human
serum
procedur
sitespecif
analysi
glycoprotein
nglycan
process
summar
figur
consist
follow
key
stage
first
stage
buffer
exchang
glycoprotein
need
dissolv
buffer
contain
nonvolatil
salt
step
glycoprotein
denatur
alkyl
ph
step
minim
nonenzymat
deamid
retain
protein
sequenc
coverag
protein
digest
sever
differ
proteas
treatment
includ
tripl
digest
chymotrypsin
combin
trypsin
chymotrypsin
order
maxim
sequenc
coverag
increas
confid
detect
glycosit
step
second
stage
step
proteas
denatur
heat
prevent
incorpor
owat
c
termini
peptid
subsequ
pngase
f
treatment
third
stage
step
sequenti
endoglycosidas
treatment
employ
creat
uniqu
mass
signatur
rel
predict
amino
acid
sequenc
peptid
glycosit
occupi
da
occupi
highmannosehybrid
da
complextyp
glycan
da
fig
result
sampl
subject
lcmsm
analysi
step
data
process
identif
quantit
peptid
three
glycosyl
state
done
use
integr
proteom
pipelin
softwar
packag
stage
step
data
extract
ms
raw
file
rawconvert
process
use
multipl
compon
softwar
packag
step
past
decad
substanti
progress
sitespecif
glycosyl
analysi
purifi
glycoprotein
exemplari
perhap
relev
protocol
work
env
desair
cripsin
group
method
develop
two
group
focu
character
intact
glycopeptid
without
enrich
glycopeptid
prior
ms
analysi
thu
provid
complementari
inform
individu
glycoform
glycosit
howev
milligram
quantiti
materi
may
requir
method
attribut
part
rel
low
ioniz
effici
glycopeptid
part
fact
glycopeptid
actual
mixtur
mani
differ
glycoform
although
complex
reduc
use
two
proteas
chymotrypsin
trypsin
identif
form
glycopeptid
multipl
nglycan
still
challeng
even
use
combin
cid
etd
fragment
quantit
measur
also
challeng
due
unknown
ioniz
glycopeptid
differ
nglycan
speci
ms
analysi
moreov
limit
inform
site
occup
due
markedli
differ
ioniz
effici
peptid
correspond
glycopeptid
andor
enrich
glycopeptid
prior
ms
analysi
method
use
endoglycosidas
identifi
glycosit
long
use
bind
hydrazideactiv
bead
enrich
use
lectin
peptid
releas
use
pngase
f
glycosyl
asparagin
convert
aspart
acid
da
mass
shift
allow
indirect
identif
glycosit
releas
peptid
altern
purifi
protein
pngase
f
appli
directli
site
occup
glycosyl
site
determin
measur
ratio
peptid
glycosit
contain
asparagin
aspart
acid
esim
analysi
comparison
protocol
describ
addit
second
endoglycosidas
endo
h
provid
addit
inform
extent
glycan
process
addit
degre
site
occup
proteolysi
combin
proteas
glycoprotein
denatur
alkyl
ph
instead
mildli
alkalin
ph
minim
nonenzymat
deamid
asn
asp
complic
data
analysi
maxim
sequenc
coverag
number
differ
proteas
digest
use
includ
digest
chymotrypsin
combin
trypsin
chymotrypsin
combin
argc
trypsin
elastas
subtilisin
tripl
digest
step
note
combin
proteolyt
digest
essenti
detect
glycosit
heavili
glycosyl
protein
larg
molecular
weight
hiv
env
trimer
spike
glycoprotein
middl
east
respiratori
syndrom
coronaviru
merscov
protein
tripl
digest
alon
abl
identifi
glycosit
glycoprotein
contain
glycosit
wherea
glycoprotein
combin
tripl
digest
chymotrypsin
enough
gener
detect
peptid
contain
glycosyl
site
anoth
benefit
use
multipl
proteas
includ
trypsin
nonspecif
proteas
produc
sequenc
ladder
contain
seri
peptid
variabl
number
amino
acid
residu
side
glycosit
allow
highli
confid
identif
given
glycosit
supplementari
tabl
singl
glycoprotein
simpl
mixtur
eg
virus
use
multipl
proteas
allow
much
higher
confid
detect
semiquantit
analysi
three
state
glycosyl
glycosit
howev
morecomplex
mixtur
eg
cell
plasma
use
specif
proteas
trypsin
result
reduc
complex
identif
glycosit
retain
abil
detect
three
differ
glycosyl
state
anoth
key
aspect
protocol
volatil
salt
ammonium
bicarbon
ammonium
acet
use
column
purif
need
result
high
specif
protocol
requir
start
materi
next
stage
pngase
f
treatment
employ
deglycosyl
glycoprotein
result
convers
asn
asp
upon
remov
carbohydr
mass
chang
carri
water
step
residu
activ
trypsin
proteas
use
proteolysi
incorpor
c
termini
peptid
deglycosyl
step
result
high
falseposit
identif
peptid
may
glycosit
avoid
denatur
proteas
use
protocol
heat
prior
deglycosyl
step
sequenti
endoglycosidas
treatment
sequenti
treatment
glycopeptid
endo
h
follow
pngase
f
employ
gener
differ
mass
signatur
glycosit
contain
glycan
highmannosehybridtyp
glycan
complextyp
glycan
step
fig
endoglycosidas
digest
highli
effici
progress
rapidli
complet
deglycosyl
reaction
conduct
h
minim
nonenzymat
deamid
occur
step
remov
nglycan
increas
ioniz
effici
peptid
allow
us
local
glycosyl
site
peptid
multipl
modif
challeng
analysi
intact
glycopeptid
supplementari
fig
principl
deglycosyl
peptid
analyz
type
lcmsm
step
highresolut
mass
spectromet
orbitrap
elit
provid
satisfactori
sequenc
coverag
glycoprotein
instrument
higher
scan
speed
orbitrap
fusion
orbitrap
lumo
sensit
gener
sever
time
msm
spectra
given
sampl
orbitrap
elit
thu
abl
provid
sitespecif
glycanprocess
inform
site
may
miss
result
gener
orbitrap
elit
result
heavi
glycosyl
larg
molecular
weight
glycoprotein
although
singledimens
separ
suffici
character
sitespecif
glycosyl
purifi
protein
multidimension
protein
identif
technolog
mudpit
peptid
systemat
separ
base
charg
first
dimens
hydrophob
second
acceler
measur
sitespecif
nglycan
process
glycoprotein
complex
protein
sampl
ideal
glycoprotein
digest
least
two
technic
replic
analyz
ms
instrument
invertas
produc
yeast
saccharomyc
cerevisia
glycoprotein
bovin
serum
known
occupi
highmannosetyp
complextyp
glycan
respect
use
control
test
complet
endoglycosidas
treatment
check
overal
success
protocol
nonenzymat
deamid
asn
residu
andor
incorp
c
terminu
seen
total
peptid
pipett
mm
ammonium
acet
filter
urea
centrifug
devic
min
repeat
step
least
two
time
critic
step
complet
buffer
exchang
import
extens
wash
filter
contain
glycoprotein
least
three
time
mm
ammonium
acet
ph
critic
step
minim
nonenzymat
deamid
acid
buffer
mm
ammonium
acet
ph
use
instead
mildli
alkalin
buffer
buffer
exchang
wash
filter
membran
mm
ammonium
acet
ph
collect
solut
store
lowproteinbind
microcentrifug
tube
repeat
step
least
four
time
combin
fraction
critic
step
wash
filter
membran
buffer
least
five
time
buffer
exchang
order
achiev
maximum
recoveri
protein
paus
point
solut
store
week
liquid
nitrogen
lyophil
solut
room
temperatur
least
h
critic
step
volatil
salt
ammonium
acet
ad
buffer
import
complet
remov
lyophil
dissolv
glycoprotein
urea
mm
ammonium
acet
ph
place
solut
room
temperatur
h
critic
step
acid
buffer
mm
ammonium
acet
use
sampl
prepar
instead
mildli
alkalin
buffer
possibl
order
keep
nonenzymat
deamid
minimum
add
mm
dtt
final
concentr
mm
incub
solut
h
critic
step
spin
min
solut
wall
microcentrifug
tube
ad
dtt
add
freshli
prepar
mm
iodoacetamid
final
concentr
mm
incub
solut
dark
room
temperatur
min
critic
step
preserv
activ
iodoacetamid
prepar
iodoacetamid
solut
immedi
use
unstabl
perform
alkyl
step
dark
iodoacetamid
lightsensit
bufferexchang
mm
ammonium
bicarbon
ph
use
centrifug
filter
membran
nomin
molecular
weight
limit
kda
critic
step
complet
buffer
exchang
import
wash
filter
least
three
time
mm
ammonium
bicarbon
g
min
dispens
sampl
five
equal
aliquot
follow
proteolyt
digest
critic
step
dri
glycoprotein
denatur
may
fulli
solubl
buffer
lyophil
paus
point
sampl
store
liquid
nitrogen
least
week
protocol
natur
protocol
proteas
treatment
time
h
five
aliquot
contain
denatur
glycoprotein
subject
treatment
multipl
proteas
combin
proteas
involv
argc
follow
trypsin
option
elastas
option
b
subtilisin
option
c
aliquot
ac
later
combin
tripl
digest
sampl
step
remain
two
aliquot
digest
chymotrypsin
option
combin
trypsin
chymotrypsin
option
e
argc
follow
trypsin
add
argc
one
aliquot
contain
denatur
glycoprotein
enzymeprotein
ratio
wtwt
bring
final
volum
mm
ammonium
bicarbon
ph
add
dtt
edta
final
concentr
mm
mm
respect
critic
step
argc
abl
cleav
c
terminu
arginin
residu
includ
site
next
prolin
result
increas
sequenc
coverag
combin
trypsin
digest
ii
incub
solut
h
iii
lyophil
result
peptid
mixtur
least
h
remov
water
volatil
salt
iv
redissolv
peptid
mixtur
mm
ammonium
acet
ph
v
add
sequencinggrad
modifi
trypsin
solut
trypsinprotein
ratio
wtwt
critic
step
sequencinggrad
modifi
trypsin
abl
digest
glycoprotein
ph
preserv
adequ
digest
effici
combin
peptid
mixtur
deriv
step
tripl
digest
sampl
separ
heat
combin
tripl
digest
sampl
step
sampl
gener
digest
chymotrypsin
step
combin
trypsin
chymotrypsin
step
troubleshoot
filter
result
gener
dtaselect
softwar
glycomotiffilt
remov
peptid
andor
modif
locat
motif
nxst
x
amino
acid
residu
except
prolin
critic
step
peptid
modif
locat
consensu
motif
manual
check
remov
asparagin
residu
locat
motif
consid
potenti
glycosyl
site
multipl
spectra
hit
modif
contain
motif
consist
detect
verif
need
potenti
glycosyl
site
start
labelfre
analysi
use
censu
anoth
compon
softwar
packag
paramet
set
find
miss
peptid
enabl
mass
toler
ppm
retent
time
toler
min
critic
step
ion
inject
time
use
normal
result
peak
area
determin
abund
peptid
raw
file
sum
ion
intens
peak
area
identifi
charg
state
critic
step
improv
accuraci
method
set
peptid
modif
consid
least
one
three
peak
area
least
note
purifi
glycoprotein
load
onto
column
present
studi
valu
empir
determin
optim
distinguish
inform
spectral
nois
vari
instrument
instrument
control
experi
done
use
wellcharacter
model
glycoprotein
invertas
occupi
highmannos
glycan
glycoprotein
occupi
complextyp
glycan
set
peak
area
threshold
peak
area
valu
depend
type
lc
system
mass
spectromet
use
appropri
threshold
need
determin
instrument
type
troubleshoot
combin
data
deriv
two
three
technic
replic
analysi
ms
run
separ
protocol
use
determin
sitespecif
nglycan
process
glycoprotein
wide
use
strategi
glycoprotein
digest
specif
proteas
trypsin
result
glyco
peptid
suitabl
lcmsm
analysi
glycosyl
peptid
howev
much
lower
ioniz
effici
ms
analysi
rel
peptid
thu
milligram
quantiti
materi
gener
use
typic
glycoproteom
method
character
glycopeptid
multipl
glycosit
msm
still
challeng
even
combin
differ
type
fragment
techniqu
quantit
measur
glycopeptid
complic
fact
ioniz
effici
glycopeptid
differ
variabl
glycoform
protocol
describ
altern
way
overcom
problem
use
combin
proteolyt
digest
follow
sequenti
endoglycosidas
treatment
one
distinguish
featur
protocol
use
sequenti
treatment
glycopeptid
endoglycosidas
endo
h
follow
pngase
f
creat
uniqu
mass
signatur
glycosit
nglycan
highmannosetyp
glycan
complextyp
glycan
strategi
convert
glycoproteom
analysi
proteom
analysi
result
higher
sensit
protocol
sampl
need
complet
analysi
key
success
sequenti
endoglycosidas
treatment
proceed
complet
avoid
misassign
nglycan
process
statu
end
appli
protocol
assess
sitespecif
nglycan
process
two
wellcharacter
model
glycoprotein
invertas
produc
yeast
cerevisia
glycoprotein
bovin
serum
glycosit
invertas
occupi
underprocess
oligomannos
glycoprotein
fulli
process
complextyp
glycosyl
fig
nglycosit
glycoprotein
identifi
multipl
msm
spectra
rang
per
site
supplementari
tabl
low
percentag
spectra
hit
contain
nonenzymat
deamid
oincorpor
c
termini
peptid
found
among
spectra
hit
identifi
attribut
complet
denatur
proteas
use
supplementari
tabl
describ
procedur
section
well
previou
studi
set
peptid
modif
consid
least
one
three
peak
area
least
expect
nglycosit
invertas
identifi
entir
highmannosetyp
glycosyl
site
occup
glycosit
except
site
fig
b
contrast
five
nglycosit
glycoprotein
complet
complextyp
glycosyl
site
occup
five
site
fig
result
indic
sequenti
endoglycosidas
treatment
reach
complet
anoth
major
assumpt
endoglycosidasetr
peptid
glycosit
unoccupi
occupi
highmannos
glycan
complextyp
glycan
detect
equal
ms
analysi
test
assumpt
env
trimer
express
presenc
kifunensin
highmannos
select
model
protein
hereaft
refer
nglycan
first
remov
sequenti
endoglycosidas
treatment
expect
glycosit
compris
highmannosetyp
glycosyl
green
bar
indic
kifunensin
treatment
effect
highmannos
glycan
fig
hand
pngase
f
treatment
also
appli
releas
nglycan
result
peptid
homogen
modif
purpl
bar
fig
result
two
sampl
mix
molar
ratio
order
assess
ms
detect
glycotyp
fig
peptid
modif
detect
glycosit
ratio
suggest
slightli
increas
sensit
peptid
modif
synthet
peptid
carri
asparagin
unoccupi
aspart
acid
pngase
ftreat
nacetylglucosaminelink
asparagin
residu
glycosyl
site
display
similar
ioniz
effici
esim
analysi
indic
protocol
abl
semiquantit
assess
sitespecif
nglycan
process
glycoprotein
although
protocol
initi
develop
analysi
sitespecif
nglycan
process
hiv
env
trimer
applic
analysi
sitespecif
nglycan
process
recombin
glycoprotein
therapeut
fig
b
serum
glycoprotein
fig
solubl
membranebound
envelop
glycoprotein
virus
fig
also
like
use
character
glycoprotein
process
complex
system
whole
cell
due
high
sensit
sitespecif
nglycan
process
recombinantli
produc
therapeut
glycoprotein
includ
igg
igm
determin
fig
b
human
serum
igg
contain
major
isotyp
found
entir
complextyp
glycosyl
consist
previou
studi
fig
five
nglycosit
igm
major
antibodi
produc
primari
immun
respons
three
site
shown
complet
occupi
complextyp
structur
wherea
two
site
primarili
highmannosetyp
glycosyl
fig
glycosit
proxim
domain
thu
poor
substrat
ost
found
partial
glycosyl
agreement
previou
studi
abnorm
glycosyl
serum
glycoprotein
common
featur
variou
human
diseas
cancer
congenit
disord
glycosyl
cdg
particular
serum
transferrin
first
use
diagnos
abnorm
glycosyl
cdg
patient
normal
transferrin
two
nglycosyl
site
fulli
occupi
wherea
type
cdg
increas
monoglycosyl
transferrin
found
due
defect
oligosaccharid
assembl
transfer
glycoprotein
patient
analysi
sitespecif
nglycan
process
commerci
avail
human
serum
transferrin
reveal
two
glycosit
protein
entir
complextyp
glycosyl
fig
line
previou
studi
anoth
serum
glycoprotein
fetuin
also
found
entir
complextyp
glycosyl
full
occup
two
site
partial
glycosyl
third
glycosit
site
occup
fig
membranebound
envelop
glycoprotein
variou
virus
merscov
protein
hiv
env
trimer
target
neutral
antibodi
thu
focu
vaccin
develop
nlink
glycan
envelop
glycoprotein
serv
shield
protect
underli
protein
immun
surveil
thu
confound
develop
effect
vaccin
virus
importantli
neutral
antibodi
virus
glycandepend
epitop
suggest
vaccin
design
effort
would
benefit
greatli
understand
nglycan
process
statu
glycosyl
site
merscov
protein
larg
trimer
kda
nlink
glycan
per
monom
compris
two
noncoval
associ
subunit
character
sitespecif
nglycan
process
prefusionstabil
merscov
protein
ectodomain
mer
reveal
glycosit
protein
fulli
occupi
except
site
fig
highmannos
glycan
predominantli
found
residu
wherea
region
protein
includ
rbd
two
subdomain
contain
glycosit
occupi
larg
complextyp
glycan
fig
glycan
epitop
antibodi
report
mask
antibodi
recognit
found
complextyp
structur
note
observ
proteas
use
bias
specif
glycotyp
glycosit
recombin
influenza
haemagglutinin
ha
three
highmannos
four
fulli
complextyp
glycosyl
rest
occupi
mixtur
highmannos
complextyp
glycan
fig
strike
observ
site
occupi
anoth
site
occupi
ha
glycoprotein
also
appli
protocol
benchmark
hiv
env
trimer
result
identif
glycosit
spectra
hit
per
glycosit
fig
glycosit
occupi
except
site
larg
occupi
highmannos
four
complextyp
glycosyl
six
site
mixtur
highmannos
complextyp
glycan
particular
glycosit
highmannos
patch
region
found
occupi
predominantli
underprocess
oligomannos
consist
previou
studi
glycan
critic
bind
bnab
hiv
env
compos
predominantli
highmannos
structur
confirm
glycan
composit
site
describ
previou
structur
studi
interestingli
highmannos
complextyp
glycan
identifi
glycosyl
site
match
pathway
nglycan
process
highmannos
structur
first
trim
man
man
addit
termin
monosaccharid
defin
complextypehybrid
glycan
compar
result
protein
obtain
intact
glycopeptid
level
thu
site
predominantli
occupi
man
highmannos
glycosyl
wherea
site
occupi
mixtur
process
highmannos
structur
man
man
simpl
complextyp
structur
occupi
mixtur
highmannos
complextyp
glycan
believ
protocol
wide
interest
proteom
glycom
field
use
mani
outsid
field
want
gain
highlevel
inform
glycoprotein
investig
data
support
find
studi
avail
correspond
author
upon
reason
request
inform
experiment
design
avail
life
scienc
report
summari
